Evidence map›Paper›PMID 39472345›Full record

Trial reportWorld journal of urology2024

Regression and growth rates in androgen deprivation therapy for advanced castration-sensitive prostate cancer.

Leandro Blas, Masaki Shiota, Hideyasu Matsuyama, Toshiyuki Kamoto, Hideki Enokida, Naohiro Fujimoto, Hideki Sakai, Tsukasa Igawa, Tomomi Kamba, Akira Yokomizo and 2 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in World journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Leandro BlasDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Masaki ShiotaDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan. shiota.masaki.101@m.kyushu-u.ac.jp.ORCID http://orcid.org/0000-0002-3306-4858
Hideyasu MatsuyamaDepartment of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan.
Toshiyuki KamotoDepartment of Urology, Faculty of Medicine, Miyazaki University, Miyazaki, Japan.
Hideki EnokidaDepartment of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Naohiro FujimotoDepartment of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Hideki SakaiDepartment of Urology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Tsukasa IgawaDepartment of Urology, School of Medicine, Kurume University, Kurume, Japan.
Tomomi KambaDepartment of Urology, Kumamoto University, Kumamoto, Japan.
Akira YokomizoDepartment of Urology, Harasanshin Hospital, Fukuoka, Japan.
Seiji NaitoDepartment of Urology, Harasanshin Hospital, Fukuoka, Japan.
Masatoshi EtoDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNo study has compared cancer regression (d) and growth (g) rates in patients with advanced castration-sensitive prostate cancer (CSPC) treated with androgen deprivation therapy. The comparison of d and g rates provides insight into the differential impact of ADT regimens on tumor dynamics, potentially guiding more personalized treatment strategies. Therefore, we aimed to estimate these rates and evaluate their impact on survival outcomes.

methodsSequential prostate-specific antigen (PSA) data was obtained from the KYUCOG-1401 trial including patients with advanced CSPC randomized to gonadotropin-releasing hormone (GnRH) antagonist (group A) and GnRH agonist plus bicalutamide (group B). d and g rates were estimated by applying mathematical models and were compared in subgroups. PSA-progression-free survival (PSA-PFS), radiographic progression-free survival (rPFS), and overall survival (OS) were compared by lower and higher than the median of these rates.

resultsPatients with higher PSA and higher extent of disease score at enrollment presented higher d rates (0.03965 vs. 0.03546, p = 0.0006) and (0.03947 vs. 0.03587, p = 0.0113) for groups A and B, respectively. The median d rate was lower for group A than group B (0.03306 vs. 0.039965, respectively [p = 0.0002]). The median g rate was higher for group A than group B (0.00016 vs. 0.00002, respectively [p = 0.0014]). The g rate, but not the d rate discriminated PSA-PFS, rPFS, and OS.

conclusionOur results suggest that GnRH agonist plus bicalutamide reduced PSA level faster and suppressed PSA rising longer than GnRH antagonist. Moreover, measuring the g rate can predict PSA-PFS, rPFS, and OS in patients with advanced CPSC treated with androgen deprivation therapy. These findings suggest that incorporating g rate measurements into clinical practice could improve prognostic accuracy and guide treatment decisions in advanced CSPC.

Indexed as

Androgen AntagonistsAnilidesNitrilesProstate-Specific AntigenTosyl CompoundsAgedGonadotropin-Releasing HormoneHumansMaleMiddle AgedNeoplasm StagingProstatic NeoplasmsSurvival RateAndrogen AntagonistsAnilidesbicalutamideGonadotropin-Releasing HormoneNitrilesProstate-Specific AntigenTosyl CompoundsCastration-sensitive prostate cancerCombined androgen blockadeGnRH antagonistGrowth rateRegression rate

Identifiers

PMID39472345

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.